1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Dr Reddy’s launches Pamorelin LA in India

Used for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer

 
PRLog - Dec. 7, 2012 - HYDERABAD, India -- Dr Reddy’s launches PamorelinÒ LA in India

Used for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer

Hyderabad, India – December 07, 2012
– Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced that it has launched PamorelinÒ LA in India on December 03, 2012, under an exclusive marketing and sales agreement with Debiopharm GroupTM, Switzerland. PamorelinÒ LA is used for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.

PamorelinÒ LA will be imported in bulk from Debio Recherche Pharmaceutique (Debio R.P.). It will be made available primarily to urologists and oncologists across India.

Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Pamorelin® LA (active ingredient : triptorelin)


Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). In 1982, Debiopharm in-licensed Triptorelin. Since then, it has developed and registered three slow-release formulations (1, 3 and 6 months) of Triptorelin Pamoate in Europe and the US.  

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa and Romania.

For more information, log on to: www.drreddys.com

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group™, please visit: www.debiopharm.com.

About Debio R.P.

Debio Recherche Pharmaceutique (Debio R.P.), based in Martigny (Switzerland), is a pharmaceutical research, development and production company that has been Swissmedic and ANVISA (Brazil) certified, as well as inspected and registered by the American Food and Drug Administration (FDA) and the KFDA (South Korea). Debio R.P. is active in the discovery, formulation and development of peptides. Debio R.P. forms part of Debiopharm Group™ and employs 130 people, half of whom are university graduates or engineers.

Dr. Reddy’s Laboratories

Debiopharm

Media:

S Rajan
rajans@drreddys.com / +91-40-49002445

Investors and Financial Analysts:
Kedar Upadhye
kedaru@drreddys.com / +91-40-66834297

Saunak Savla
saunaks@drreddys.com (mailto:raghavenderr@drreddys.com) /+91-40-49002135

Milan Kalawadia (USA)
mkalawadia@drreddys.com / +1 908-203-4931

Debiopharm S.A. Contact      

Maurice Wagner

Director Corporate Affairs & communication

Tel.: +41 (0)21 321 01 11

Fax: +41 (0)21 321 01 69

mwagner@debiopharm.com

Additional Media Contacts

In London

Maitland

Brian Hudspith

Tel: +44 (0)20 7379 5151

bhudspith@maitland.co.uk

In New York

Russo Partners, LLC

Martina Schwarzkopf, Ph.D.

Account Executive

Tel: +1 212-845-4292

Fax: +1 212-845-4260

martina.schwarzkopf@russopartnersllc.com

--- End ---

Click to Share

Contact Email:
***@drreddys.com
Source:Dr. Reddy’s Dr. Reddy’s Laboratories Ltd.
Location:Hyderabad - Andhra Pradesh - India
Industry:Pharma Industry
Tags:Pamorelin
Shortcut:prlog.org/12038693
Verified Account Email Address
Verified Account Phone Number

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share